LENSAR

Name

LENSAR

Legal name

LENSAR, Inc.

Website

https://lensar.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Surgical Laser Systems

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industry

Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)

Keywords

• Femtosecond cataract laser
• Refractive cataract surgery
• Ophthalmic surgical systems
• Toric IOL alignment
• Robotic laser platform

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. System Sales (Capital Equipment): Sale of ALLY Robotic Cataract Laser Systems and LENSAR Laser Systems to eye surgery centers and hospitals. Represents the non-recurring portion of revenue, though declining due to market uncertainty around terminated Alcon merger.
2. Recurring Revenue (Service/Consumables): Recurring revenue from service contracts, disposables, and consumables associated with installed laser systems. Growing as installed base expands - reached 94% of total revenue in Q1 2026 ($12.6M), up 9% year-over-year.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

LENSAR designs, manufactures, and sells femtosecond cataract laser systems — the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System — to ophthalmic surgeons and eye surgery centers for refractive cataract surgery. Revenue comes from the sale of these capital equipment systems plus recurring service contracts and consumables tied to an installed base of approximately 440 systems. The company complements its hardware with proprietary imaging and software (Streamline, Cataract Density Imaging, IntelliAxis Refractive Capsulorhexis, Iris Registration) that automate surgical planning and precision.

Product overview

LENSAR is a medical technology company specializing in femtosecond laser systems for refractive cataract surgery. The product portfolio centers on two core platforms: the LENSAR Laser System and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System serves as the foundational femtosecond laser platform with proprietary imaging technologies including Cataract Density Imaging, Scheimpflug imaging, and 3-D confocal structured illumination. The ALLY System represents the next generation, combining dual-pulse femtosecond laser technology with advanced imaging in a single compact system. Both platforms share key software features including Streamline upgrades (I through IV), IntelliAxis Refractive Capsulorhexis for toric IOL alignment, Iris Registration for cyclorotation adjustment, and arcuate incision planning. The systems integrate with pre-operative diagnostic devices including Pentacam, Cassini, Nidek OPD-Scan III, and Topcon Aladdin for wireless data transfer.

Differentiator

Problem solved

Functional benefit

Brands

• ALLY: ALLY Adaptive Cataract Treatment System - FDA-cleared robotic cataract laser system combining dual-pulse femtosecond laser with advanced imaging technology
• LENSAR Laser System
• Streamline
• IntelliAxis Refractive Capsulorhexis
• Cataract Laser with Augmented Reality

Products and services

• ALLY Adaptive Cataract Treatment System FDA-cleared robotic cataract laser system that combines dual-pulse femtosecond laser technology with advanced imaging in a single compact system to enable sterile FLACS procedures for ophthalmic surgeons and eye surgery centers.
• LENSAR Laser System Premier femtosecond laser cataract treatment platform with proprietary imaging including Scheimpflug imaging, Cataract Density Imaging, and IntelliAxis Refractive Capsulorhexis, designed for refractive cataract surgeons seeking superior outcomes and faster visual recovery.
• Streamline IV Software Upgrade Software upgrade for the LENSAR Laser System that adds IntelliAxis Refractive Capsulorhexis, enabling precise toric IOL alignment by marking the steep axis on the capsular rim and eliminating parallax from corneal markings.
• Streamline III Software Upgrade Software upgrade for the LENSAR Laser System that expanded wireless pre-operative diagnostic integration to support successful refractive outcomes.
• IntelliAxis Refractive Capsulorhexis Proprietary technology incorporated into the LENSAR and ALLY platforms that places small tabs on the capsular rim during capsulorhexis to clearly identify the intended axis for precise toric IOL alignment.
• Cataract Density Imaging Proprietary imaging module that automatically grades cataract density (I-V), identifies nucleus location and lens layers, and enables adaptive fragmentation patterns optimized for tissue-specific treatment and reduced phaco energy.
• Iris Registration Automated software module that confirms image compatibility at capture, detects eye cyclorotation, and automatically adapts treatment to replace less precise preoperative manual ink markings for increased laser precision.

Quantifiable outcome

• Up to 100% of patients within 0.50D for toric IOL treatment guided by IntelliAxis
• +10 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature10 records

Partnerships

One partnership is on record.

• AlconterminatedOthers · 16 March 2026Planned acquisition of LENSAR by Alcon for approximately $356-430 million was mutually terminated on March 16, 2026 after FTC indicated opposition to the deal. The FTC determined the deal would have combined the two dominant players in femtosecond laser-assisted cataract surgery (FLACS), threatening prices and innovation. LENSAR retained a $10 million deposit. Deal originally signed in March 2025.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic medical device incumbent offering surgical microscopes, IOLs, and laser systems including VisuMax. While broader in scope, Zeiss is a relevant peer in the premium/refractive cataract surgical equipment market.
• HOYA Corporation: HOYA Surgical Optics supplies intraocular lenses and ophthalmic surgical products used in cataract surgery, serving many of the same ASC and hospital customers as LENSAR with overlapping premium IOL positioning.
• Bausch + Lomb: Bausch + Lomb (Bausch Health) is a diversified ophthalmic device and pharmaceutical company that competes across cataract surgery IOLs, viscoelastics, and surgical instruments, overlapping with LENSAR's customer base of cataract surgeons.

Direct peers

• Alcon: Alcon markets the LenSx femtosecond laser system for cataract surgery, the primary direct competitor to LENSAR's ALLY and LENSAR Laser Systems. The FTC identified Alcon and LENSAR as the two dominant FLACS players in its opposition to the proposed $356-430M acquisition.
• Johnson & Johnson Vision: J&J Vision (part of Johnson & Johnson) sells the Catalys femtosecond laser for cataract surgery, a directly comparable FLACS platform competing head-to-head with LENSAR and Alcon in premium cataract surgery centers globally.

Others

• Nidek: Nidek produces ophthalmic diagnostic devices including the OPD-Scan III that integrates with LENSAR's Streamline. While not a direct FLACS competitor, Nidek is a relevant ecosystem peer in refractive cataract surgical planning.
• Topcon Corporation: Topcon manufactures ophthalmic diagnostic equipment (including the Aladdin biometer that integrates with LENSAR's Streamline software). As an integration partner and adjacent diagnostic device vendor, Topcon is a relevant ecosystem peer.

Regional players

• Glaukos Corporation: Glaukos is a US-focused ophthalmic medical device company specializing in micro-invasive glaucoma surgery (MIGS). While its core focus is glaucoma rather than cataract surgery, it serves many of the same ASC customers and competes for similar ophthalmic capital budgets.
• iCare (Revenio Group): iCare/Revenio provides ophthalmic diagnostic and imaging devices used in cataract and glaucoma workflows. As a smaller international ophthalmic device player, it represents a regional/comparable peer in the broader ophthalmic equipment ecosystem.

Emerging players

• STAAR Surgical: STAAR Surgical specializes in implantable collamer lenses (ICLs/EVO ICL) for refractive vision correction, a smaller ophthalmic player with adjacent refractive surgery technology relevant to LENSAR's premium IOL positioning.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lensar-inc-
• Xx.com/LensAR

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds14 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LENSAR